• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Eric Floyd, Cephalon


Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-06-01-2008
Volume 0
Issue 0


Eric Floyd

VP, Worldwide Regulatory Affairs, Cephalon

BIGGEST HIT: 3 NDAs in one year

ROLE MODEL: Aventis' R&D head Frank Douglas "who moved to Germany, and learned the language and lifestyle to lead a global company"

Eric Floyd pulls no punches about Big Pharma's famous fear of change. "If you think outside the box, you can be viewed as a threat. If you are perceived as a threat, they challenge and frustrate you," he says. That's how Floyd found his way to Cephalon, one of the industry's fastest-growing biotechs

Eric Floyd

Like so much else in pharma, what's required from regulatory has changed so much and so fast that "the old mindsets and models are no longer sustainable," says Floyd. "We're seeing 45-year-old CEOs because they understand the challenges—and because the boards understand it, too."

At Cephalon, he finds the flexibility, fast-response, and forward-thinking that's missing at the large caps—and mandatory at the predictably unpredictable FDA. "We need to anticipate the agency's concerns, and build them into our clinical programs and marketing strategies," he says. "There's no guidance yet with the new REMS, so we need to influence change internally." Given FDA's knockdown of Cephalon's Fentora application for noncancer indications, Floyd will get the chance to have influence as Cephalon ramps up its controls over the prone-to-abuse product in its argument to the agency.

Related Videos
Related Content